Screener
Immunovant, Inc. IMVT Shares (Diluted)
Shares (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Immunovant, Inc. in its filing.
Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding.
The source filing: Immunovant, Inc.’s 10-K, filed May 20, 2026.
- Filed
- May 20, 2026, 7:28 AM EDT
- Fiscal year
- FY2026
- Accession
- 0001764013-26-000064
| Line item | Years Ended March 31, 2026 | Years Ended March 31, 2025 | Years Ended March 31, 2024 |
|---|---|---|---|
| Total operating expenses | 532,902 | 438,152 | 282,709 |
| Interest income, net | (25,330) | (24,732) | (24,948) |
| Other (income) expense, net | (2,181) | (471) | 1,008 |
| Loss before provision for income taxes | (505,391) | (412,949) | (258,769) |
| Provision for income taxes | 215 | 891 | 567 |
| Net loss | $(505,606) | $(413,840) | $(259,336) |
| Net loss per common share — basic and diluted | $(2.77) | $(2.73) | $(1.88) |
| Weighted average common shares outstanding — basic and diluted | 182,421,233 | 151,573,553 | 138,100,577 |
Item 8. Financial Statements and Supplementary Data
FAQ
- What is Immunovant, Inc.'s shares (diluted)?
- Immunovant, Inc. (IMVT) reported shares (diluted) of 182.4M in Q1 2026.
- How has Immunovant, Inc.'s shares (diluted) changed year-over-year?
- Immunovant, Inc.'s shares (diluted) increased by 20.4% year-over-year, from 151.6M to 182.4M.
- What is the long-term trend for Immunovant, Inc.'s shares (diluted)?
- Over 4 years (2022 to 2026), Immunovant, Inc.'s shares (diluted) has grown at a 13.2% compound annual growth rate (CAGR), from 431.8M to 708.5M.
- What does shares (diluted) mean?
- The weighted-average shares outstanding plus all potentially dilutive shares from stock options, RSUs, convertible securities, and warrants, using the treasury stock method.
Ask your AI about Immunovant, Inc.'s shares (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude